Androgens
are male sex hormones responsible for masculine characteristics such
ad muscular build, deeper voice, and facial hair. Most of the
androgens are produced in testes and their two most common types are
dihydrotestosterone (DHT) and testosterone. Along with normal
functions, androgens also contribute to prostate cancer cell growth,
especially during early stages of the cancer. Androgen deprivation
therapy, also called androgen suppression therapy, is used either to
reduce the production of androgens in the patient’s body or to
modulate the way androgens work, thus ultimately inhibiting growth of
prostate cancer cells.
To
Access the Free Sample Report:
https://www.coherentmarketinsights.com/insight/request-sample/2559
Androgen
Deprivation Therapy (ADT) Market Drivers
Key
players in the market are focusing on research to develop new drugs
and broaden the indication label of current drugs for treatment of
androgen deprivation therapy (ADT), which is expected to boost the
global androgen deprivation therapy (ADT) market growth over the
forecast period.
For
instance, in February 2018, Janssen Pharmaceutica, a subsidiary of
Johnson & Johnson received approval for its drug ERLEADA
(apalutamide) in treatment of non-metastatic castration-resistant
prostate cancer (CRPC). ERLEADA is a next-generation androgen
receptor inhibitor, which belongs to the class of drugs
anti-androgens and blocks the effect of testosterone to slow down the
process of tumor growth and metastasis. It is the first U.S. Food and
Drug Administration (FDA) approved drug for the treatment of patients
with non-metastatic CRPC.
Similarly,
in July 2018, Pfizer Inc. and Astellas Pharma Inc. received approval
from the U.S. FDA for XTANDI (enzalutamide) that is indicated for the
treatment of non-metastatic CRPC along with its existing indication
for CRPC. XTANDI is an androgen receptor inhibitor and works by
inhibiting the effects of testosterone, thereby slowing tumor growth
and metastasis. These factors are expected to have a positive impact
on the global androgen deprivation therapy (ADT) market growth over
the forecast period.
Androgen
Deprivation Therapy (ADT) Market Regional Analysis
Approval
for new drugs is expected to boost the global androgen deprivation
therapy (ADT) market growth over the forecast period. For instance,
in November 2017, European Commission (EC) granted approval to
Janssen-Cilag International NV (Janssen) for broadening the existing
marketing authorization for its drug Zytiga (abiraterone acetate).
The approval enables the company to include the drug in treatment of
metastatic prostate cancer’s early stages along with ADT. Such new
drug approvals are expected to propel Europe androgen deprivation
therapy (ADT) market growth over the forecast period.
Androgen
Deprivation Therapy (ADT) Market Key Players
Some
of the major players operating in the androgen deprivation therapy
(ADT) market include, Pfizer Inc., Astellas Pharma Inc., Johnson &
Johnson, Novartis International AG, Veru Inc., Sanofi S.A.,
GlaxoSmithKline plc, Bayer AG, Orion Corporation, and AstraZeneca
Plc.
Androgen
Deprivation Therapy (ADT) Market Taxonomy
The
global androgen deprivation therapy (ADT) market is segmented on the
basis of drug class, route of administration, distribution channel,
and regions.
By Drug
Class
-
Antiandrogens
-
Flutamide
-
Bicalutamide
-
Nilutamide
-
Enzalutamide
-
-
Luteinizing hormone-releasing hormone (LHRH) agonists
-
Leuprolide
-
Goserelin
-
Triptorelin
-
Histrelin
-
-
LHRH antagonist
-
Degarelix
-
Abiraterone
-
-
Others
Get
Full Access of This Business Report:
https://www.coherentmarketinsights.com/ongoing-insight/androgen-deprivation-therapy-adt-market-2559
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment